» Articles » PMID: 36765597

Follicular Thyroid Adenoma and Follicular Thyroid Carcinoma-A Common or Distinct Background? Loss of Heterozygosity in Comprehensive Microarray Study

Abstract

Pre- and postsurgical differentiation between follicular thyroid adenoma (FTA) and follicular thyroid cancer (FTC) represents a significant diagnostic challenge. Furthermore, it remains unclear whether they share a common or distinct background and what the mechanisms underlying follicular thyroid lesions malignancy are. The study aimed to compare FTA and FTC by the comprehensive microarray and to identify recurrent regions of loss of heterozygosity (LOH). We analyzed formalin-fixed paraffin-embedded (FFPE) samples acquired from 32 Caucasian patients diagnosed with FTA (16) and FTC (16). We used the OncoScan™ microarray assay (Affymetrix, USA), using highly multiplexed molecular inversion probes for single nucleotide polymorphism (SNP). The total number of LOH was higher in FTC compared with FTA (18 vs. 15). The most common LOH present in 21 cases, in both FTA (10 cases) and FTC (11 cases), was 16p12.1, which encompasses many cancer-related genes, such as , and was followed by 3p21.31. The only LOH present exclusively in FTA patients (56% vs. 0%) was 11p11.2-p11.12. The alteration which tended to be detected more often in FTC (6 vs. 1 in FTA) was 12q24.11-q24.13 overlapping , MYL2, genes. FTA and FTC may share a common genetic background, even though differentiating rearrangements may also be detected.

Citing Articles

Diagnostic significance of ultrasound characteristics in discriminating follicular thyroid carcinoma from adenoma.

Xu R, Wen W, Zhang Y, Qian L, Liu Y BMC Med Imaging. 2024; 24(1):299.

PMID: 39501175 PMC: 11536847. DOI: 10.1186/s12880-024-01477-0.


Thyroid Cancer: Focus on Invasion and Metastasis Mechanisms, Therapeutic Target and Drug Treatment.

Vasko V Cancers (Basel). 2023; 15(19).

PMID: 37835455 PMC: 10571936. DOI: 10.3390/cancers15194762.

References
1.
Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G . Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res. 2011; 71(5):1792-804. DOI: 10.1158/0008-5472.CAN-10-2186. View

2.
Rakhsh-Khorshid H, Samimi H, Torabi S, Sajjadi-Jazi S, Samadi H, Ghafouri F . Network analysis reveals essential proteins that regulate sodium-iodide symporter expression in anaplastic thyroid carcinoma. Sci Rep. 2020; 10(1):21440. PMC: 7722919. DOI: 10.1038/s41598-020-78574-x. View

3.
Larousserie F, Bardel E, Coulomb Lhermine A, Canioni D, Brousse N, Kastelein R . Variable expression of Epstein-Barr virus-induced gene 3 during normal B-cell differentiation and among B-cell lymphomas. J Pathol. 2006; 209(3):360-8. DOI: 10.1002/path.1995. View

4.
Otsubo R, Matsuda K, Mussazhanova Z, Sato A, Matsumoto M, Yano H . A Novel Diagnostic Method for Thyroid Follicular Tumors Based on Immunofluorescence Analysis of p53-Binding Protein 1 Expression: Detection of Genomic Instability. Thyroid. 2019; 29(5):657-665. DOI: 10.1089/thy.2018.0548. View

5.
Bloise F, Cordeiro A, Ortiga-Carvalho T . Role of thyroid hormone in skeletal muscle physiology. J Endocrinol. 2017; 236(1):R57-R68. DOI: 10.1530/JOE-16-0611. View